NCT00658073

Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts

Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Recipients of Living Kidney Allografts

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 165 (actual)
• Sponsor: Fuzhou General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to evaluate autologous MSCs as an alternative for antibody induction therapy in renal transplantation.

Detailed description

Renal transplantation is the most common and successful type of organ transplantation. Induction therapy with antibody plus the maintenance immunosuppressive agents have greatly improved graft survival in renal transplantation. Since mesenchymal stem cells(MSCs)have been used successfully to treat graft versus host disease and show immune modulation function both in vitro and in vivo and may help in repairing damaged tissue(s), we evaluate autologous MSCs as an alternative for antibody induction therapy. Moreover, we examine if MSCs could improve the recovery of early function in transplanted kidney.

Conditions

• Renal Transplant Rejection

Interventions

Type	Name	Description
PROCEDURE	Kidney transplantation with MSCs infusion	Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
PROCEDURE	kidney transplantation without MSC infusion	kidney transplantation with standard immunosuppressive treatment regime

Timeline

• Start date: 2008-03-01
• Primary completion: 2010-09-01
• Completion: 2010-10-01
• First posted: 2008-04-14
• Last updated: 2011-03-08

Locations

1 site across 1 country: China